Breaking News

Vimpelcom Agrees to Sell 51% of Djezzy to Algeria for $2.64 Billion
Tweet TWEET

Depomed Sues Impax, Par in Patent Case Over Gralise Copy

Depomed Inc. sued the generic-drug makers Impax Laboratories Inc. (IPXL) and Par Pharmaceutical Co. (PRX) to prevent them from selling copies of Gralise, a medicine that treats pain after shingles infections.

Impax and Par are seeking U.S. Food and Drug Administration approval to sell generic versions of Gralise, according to a complaint filed April 10 in federal court in Trenton, New Jersey. Depomed, based in Menlo Park, California, said the copies for 300 and 600 milligram tablets would infringe six patents. It seeks a court order to prevent sales until the patents expire.

Impax, based in Hayward, California, confirmed in a statement today that it filed an FDA application challenging the patents. Allison Wey, a spokeswoman for Par, based in Woodcliff, New Jersey, didn’t immediately return a call seeking comment.

On March 2, Depomed also sued Actavis Group Hf, Watson Pharmaceuticals Inc. and Incepta Pharmaceuticals Co., claiming they infringed the same six Gralise patents.

The case is Depomed Inc. (DEPO) v. Impax Laboratories, 12-cv-2154, U.S. District Court, District of New Jersey (Trenton).

To contact the reporters on this story: David Voreacos in Newark, New Jersey, at dvoreacos@bloomberg.net; Felice Maranz in New York at fmaranz@bloomberg.net.

To contact the editors responsible for this story: Michael Hytha at mhytha@bloomberg.net; Andrew Cinko at cinko@bloomberg.net.

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.